Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Quarterly or Semiannual Financial Statements
- Sales of EUR 102.4 million at previous year's level - 6% increase in earnings to EUR 5.2 million - For the first time positive signs from the Rehabilitation division

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

08.02.2005

In the first half of the fiscal year 2004/05, the Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was able to slightly expand sales to EUR 102.4 million (previous year EUR 102.1 million). The earnings pursuant to DVFA/SG (IFRS) were improved to EUR 5.2 million, up EUR 0.3 million from EUR 4.9 million. The earnings per share came to EUR 0.43 following EUR 0.40 in the same period one year ago.

The increases in sales and earnings were exclusively attributable to the core division Nursing, which was able to further compensate for the continuing downtrend in the Rehabilitation unit. The Marseille-Kliniken AG provides more than three quarters of its total bed capacity in the Nursing division and recorded sales of EUR 75.4 million during the period under review compared with EUR 72.8 million in the period one year ago. The Nursing division improved the earnings pursuant to DVFA/SG (IFRS) by EUR 1.1 million to EUR 6.9 million (previous year EUR 5.8 million). Due to reconstruction work at the sites in Belzig and Leipzig the utilization rate in the Nursing segment declined slightly to 93.8% from 94.5% in the previous year. This means a decrease in the Group’s overall utilization rate from 90.6% to currently 89.6%.

In the Rehabilitation segment sales remained EUR 2.1 million below previous year’s level of EUR 28.2 million and amounted to EUR 26.1 million for the first half of the fiscal year 2004/05. Also the loss pursuant to DVFA/SG (IFRS) amounting to EUR 1.7 million (previous year loss of EUR 0.9 million) still had a negative impact on the overall results. However, it should be noted that the restructuring measures are starting to pay off. The utilization rate improved to currently 77.1% in the usually seasonally weak 2nd quarter compared with 75.6% in the 1st quarter. If this trend will continue in the following quarters, a gradual reduction in the burdens from the Rehabilitation division should be expected.

Due to the sustained favorable trends in the Nursing division, the management of Marseille-Kliniken AG expects an increase in the consolidated sales and a disproportionately stronger improvement in earnings in the fiscal year 2004/2005.

For further information please contact: Marseille-Kliniken AG Axel Hölzer CEO Alte Jakobstraße 79/80 10709 Berlin Tel.: 030 / 246 32-400 Fax: 030 / 246 32-401

end of announcement                                euro adhoc 08.02.2005 20:10:00
---------------------------------------------------------------------

Further inquiry note: Christian Hillermann c.hillermann@hillermann-consulting.de +49 (0) 40-414069-13

Branche: Pharmaceuticals
ISIN:      DE0007783003
WKN:        778300
Index:    Prime Standard, CDAX, Classic All Share, Prime All Share
Börsen:  Berliner Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Bremer Wertpapierbörse (BWB) / free trade
              Hamburger Wertpapierbörse / official dealing
              Frankfurter Wertpapierbörse / official dealing



Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: